Success Metrics

Active Trials
3(100%)

Phase Distribution

Ph phase_4
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution1 total trials
Phase 4Post-market surveillance
1(100.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Recruiting3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
3
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 41 (100.0%)

Trials by Status

recruiting3100%

Recent Activity

3 active trials
Showing 3 of 3
recruitingphase_4

Dupilumab De-escalation in Pediatric Atopic Dermatitis

NCT06116526
recruiting

Dupilumab Therapy for EGIDs

NCT07257835
recruiting

Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.

NCT06892704

Clinical Trials (3)

Showing 3 of 3 trials
NCT06116526Phase 4

Dupilumab De-escalation in Pediatric Atopic Dermatitis

Recruiting
NCT07257835

Dupilumab Therapy for EGIDs

Recruiting
NCT06892704

Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3